Related Experiment Videos

Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization

Jean-Marie Rakic1, Vincent Lambert, Carine Munaut

  • 1Department of Ophthalmology, University Hospital, Sart-Tilman, Liège, Belgium. jmrakic@chu.ulg.ac.be

Abstract

Insights

The plasminogen/plasminogen activator (Plg/PA) system is present in choroidal neovascularization (CNV). Inhibiting Plg/PA components reduced CNV development, suggesting a new treatment strategy for exudative age-related macular degeneration (AMD).

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Biochemistry

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss.
  • Exudative AMD involves abnormal blood vessel growth (choroidal neovascularization, CNV).
  • The role of the plasminogen/plasminogen activator (Plg/PA) system in CNV is not fully understood.

Purpose of the Study:

  • To investigate the presence and function of the Plg/PA system in exudative AMD.
  • To evaluate the impact of Plg/PA system components on choroidal neovascularization (CNV).

Main Methods:

  • RT-PCR to assess mRNA expression of PA members in human and experimental CNV.
  • Immunofluorescence and in situ zymography to detect PA presence and activity.
  • Gene-deficient mice models (Plg, uPA, tPA, uPAR) to study CNV development after laser injury.

Main Results:

  • Plg/PA system components were detected in both human and murine CNV.
  • Absence of Plg, uPA, or tPA significantly reduced experimental CNV development.
  • Reduced CNV was linked to modulated matrix metalloproteinase activity and fibrin accumulation.

Conclusions:

  • The Plg/PA system plays a critical role in choroidal neovascularization.
  • Modulating Plg/PA system activity shows promise for treating exudative AMD.
  • This research opens new avenues for therapeutic strategies targeting AMD.

Related Concept Videos